Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diltiazem Cyclosporine

Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction — dose-response relationship. BrJ Clin Pharmacol (1997) 44, 499-504. [Pg.1028]

Diltiazem Inhibits AV nodal conduction by slowing AV nodal conduction and prolonging AV nodal refractoriness 1.0.25 mg/kg IV load over 2 minutes 2. If necessary, 0.35 mg/kg IV over 2 minutes after first dose Continuous infusion of 5-1 5 mg/hour Oral 120-360 mg/day Inhibits elimination of cyclosporine... [Pg.118]

Fig. 20.8. P -gp-ATPase activation profiles obtained by measurements of extracellular acidification rates in living cells by means of a cytosensor physiometer. (A) Cyclosporin A ( ), progesterone (0)> trifluoperazine (A) and verapamil ( ) in LLC-MDR1 cells (B) amitriptyline ( ), calcein-AM (A), diltiazem ( ) and vinblastine (T) in LLC-MDR1 cells. Fig. 20.8. P -gp-ATPase activation profiles obtained by measurements of extracellular acidification rates in living cells by means of a cytosensor physiometer. (A) Cyclosporin A ( ), progesterone (0)> trifluoperazine (A) and verapamil ( ) in LLC-MDR1 cells (B) amitriptyline ( ), calcein-AM (A), diltiazem ( ) and vinblastine (T) in LLC-MDR1 cells.
Fig. 20.13. Potential H-bonding energy, released upon interaction with the transmembrane domains of P-gp (in arbitrary energy units, EU) for progesterone (1), propranolol (2), amitriptyline (3), diltiazem (4), amiodarone (5), colchicine (7), gramicidin S (8), daunorubicin (9), vinblastine (10), cyclosporin A, in comparison with verapamil... Fig. 20.13. Potential H-bonding energy, released upon interaction with the transmembrane domains of P-gp (in arbitrary energy units, EU) for progesterone (1), propranolol (2), amitriptyline (3), diltiazem (4), amiodarone (5), colchicine (7), gramicidin S (8), daunorubicin (9), vinblastine (10), cyclosporin A, in comparison with verapamil...
The enzyme is the principal participant in N-demethylation reactions where the substrate is a tertiary amine. The list of substrates includes erythromycin, ethylmor-phine, lidocaine, diltiazem, tamoxifen, toremifene, verapamil, cocaine, amiodarone, alfentanil and terfenadine. Carbon atoms in the allylic and benzylic positions, such as those present in quinidine, steroids and cyclosporin A, are also particularly prone to oxidation by CYP3A4, a range of substrates is illustrated in Figure 7.10. [Pg.82]

Drugs that may affect HMG-CoA reductase inhibitors include alcohol, amiodarone, antacids, azole antifungals, bile acid sequestrants, cimetidine, cyclosporine, diltiazem, erythromycin, gemfibrozil, isradipine, nefazodone, niacin, nicotinic acid, omeprazole, phenytoin, propranolol, protease inhibitors, ranitidine, rifampin, St. John s wort, and verapamil. [Pg.621]

Drugs that may be affected by SSRIs Drugs that may be affected by SSRIs include alcohol, benzodiazepines, beta blockers, buspirone, carbamazepine, cisapride, clozapine, cyclosporine, diltiazem, digoxin, haloperidol, hydantoins, lithium, methadone, mexiletine, nonsedating antihistamines, NSAIDs, olanzapine, phenothiazines, phenytoin, pimozide, procyclidine, ritonavir, ropivacaine, sumatriptan, sulfonylureas, sympathomimetics, tacrine, theophylline, tolbutamide, tricyclic antidepressants, and warfarin. [Pg.1086]

Drugs that may affect tacrolimus include nephrotoxic agents (aminoglycosides, amphotericin B, cisplatin, cyclosporine), antifungals, bromocriptine, calcium channel blockers, cimetidine, clarithromycin, danazol, diltiazem, erythromycin, methylprednisolone, metoclopramide, carbamazepine, phenobarbital, phenytoin, rifamycins, cisapride, chloramphenicol, metronidazole, nefazodone, omeprazole, protease inhibitors, macrolide antibiotics, fosphenytoin, and St. John s wort. [Pg.1938]

Drugs that may increase sirolimus blood concentrations include the following Nicardipine, verapamil, clotrimazole, fluconazole, itraconazole, clarithromycin, erythromycin, troleandomycin, cisapride, metoclopramide, bromocriptine, cimetidine, danazol, HIV-protease inhibitors, cyclosporine, diltiazem, azole antifungals. [Pg.1945]

Lovastatin (Mevacor/ Altocor) [Antilipemic/HMG-CoA Reductase Inhibitor] Uses Hypercholesterolemia Action HMG-CoA reductase inhibitor Dose 20 mg/d PO w/ PM meal may T at 4-wk intervals to 80 mg/d max or 60 mg ER tab take w/ meals Caution [X, -] Avoid w/ grapefruit juice, gemfibrozil. Contra Active liver Dz Disp Tabs SE HA GI intolerance common promptly report any unexplained muscle pain, tenderness, or weakness (myopathy) Interactions T Effects W/ grapefruit juice T risk of severe myopathy W/ azole antifungals, cyclosporine, erythromycin, gemfibrozil, HMG-CoA inhibitors, niacin T effects OF warfarin >1 effects W/ isradipine, pectin EMS t Risk of photosensitivity Rxns T effects of warfarin concurrent EtOH use t risk of liver tox diltiazem and verapamil can T risk of lovastatin tox OD Unlikely to cause life-threatening Sxs... [Pg.211]

A 47-year-old man recently received a heart transplant and is being discharged home with oral medications, including cyclosporine. The physician also prescribed diltiazem, a calcium channel blocker used for the treatment of hypertension. Since he did not have hypertension, the patient wondered why this additional drug was being prescribed. [Pg.33]

Answer Cyclosporine is an immunosuppressant drug used to prevent transplant rejections. Though an oral formulation is available, it has low bioavailability (very httle reaches the systemic circulation as intact drug). Diltiazem will inhibit cytochrome P450 3A4 in the gut. CYP3A4 is the... [Pg.33]

Cyclosporine has significant nephrotoxicity, and its toxicity can be increased by drug interactions with diltiazem, potassium-sparing diuretics, and other drugs inhibiting CYP3A. Serum creatinine should be closely monitored. Other toxicities include hypertension, hyperkalemia, hepatotoxicity, gingival hyperplasia, and hirsutism. [Pg.807]

Cyclosporine [P] Decreased cyclosporine metabolism with diltiazem, nicardipine, verapamil. [Pg.1389]

Drugs that may inhibit cytochrome P450 metabolism of other drugs include amiodarone, androgens, atazanavir, chloramphenicol, cimetidine, ciprofloxacin, clarithromycin, cyclosporine, delavirdine, diltiazem, diphenhydramine, disulfiram, enoxacin, erythromycin, fluconazole, fluoxetine, fluvoxamine, furanocoumarins (substances in grapefruit juice), indinavir, isoniazid, itraconazole, ketoconazole, metronidazole, mexile-tine, miconazole, nefazodone, omeprazole, paroxetine, propoxyphene, quinidine, ritonavir, sulfamethizole, verapamil, voriconazole, zafirlukast, and zileuton. [Pg.1402]

Calcium channel blockers are considered the drug of first choice for the treatment of posttransplant I hypertension since they increase renal blood flow. Nifedipine, isradipine and amlopidine show little interac-l tion with cyclosporine-A. Diltiazem and verapamil elevate cyclosporine-A levels. I... [Pg.73]

A4 Acetaminophen, alfentanil, amiodarone, astemizole, cocaine, cortisol, cyclosporine, dapsone, diazepam, dihydroergotamine, dihydropyridines, diltiazem, ethinyl estradiol, gestodene, indinavir, lidocaine, lovastatin, macrolides, methadone, miconazole, midazolam, mifepristone (RU 486), paclitaxel, progesterone, quinidine, rapamycin, ritonavir, saquinavir, spironolactone, sulfamethoxazole, sufentanil, tacrolimus, tamoxifen, terfenadine, testosterone, tetrahydro-cannabinol, triazolam, troleandomycin, verapamil Barbiturates, carbamazepine, macrolides, glucocorticoids, pioglitazone, phenytoin, rifampin Erythromycin, 613-hydroxy cortisol... [Pg.79]

Cyt 3A3/4 metabolizes clozapine, sertindole, quetiapine common substrates -tricyclic antidepressants, nefazodone, sertraline, carbamazepine, ethosuximide, terfenadine, benzodiazepines, diltiazem, nifedipine, verapamil, erythromycin, cyclosporine, lidocaine, quinidine, cisapride, paracetamol. Common inhibitors -nefazodone, fluvoxamine, fluoxetine, ketoconazole. [Pg.462]

It has been previously reported that inhibition of efflux pumps by various compounds can lead to enhanced absorption of drugs across the intestine (Kim 2002). P-gp can be inhibited by a range of substances that blocks its function either by acting as a high avidity substrate, like verapamil, diltiazem or cyclosporine (Gerrard et al. 2004), or by binding to it such as sulphydryl-substituted purines (Al-Shawi et al. 1994). [Pg.124]

Acyclovir Erythromycin Ivermectin Itraconazole Rifampin Actinomycin D Daunorubicin Doxorubicin Docetaxel Epirubicin Etoposide Imatinib Irinotecan Paclitaxel Vinblastine Vincristine Amprenavir Indinavir Nelfinavir Ritonavir Saquinavir Cyclosporine A Tacrolimus Digoxin Quinidine Verapamil Diltiazem Aldosterone Cortisol Corticosterone Dexamethasone Hydrocortisone Cyclosporine Metkephamid Enkephalin... [Pg.125]

CYP3A4 Inhibition Amiodarone, clarithromycin, erythromycin, cimetidine, cyclosporine, fluoxetine fluvoxamine, itraconazole, ketoconazole, nefazodone, verapamil, diltiazem HIV antivirals delaviridine, indanavire, nelfmavire, ritonavire, sequinavire Atorvastatin Lovastatin Simvastatin ... [Pg.147]

CYP3A4 inhibitors that have demonstrated P-gp inhibition include erythromycin, itraconazole, cyclosporine, diltiazem, and several protease inhibitors. As a result of considerable overlap with CYP3A4, the true effect of P-gp modulation on drug interactions involving P-gp substrates is unclear. Further, poor differentiation between P gp modulation in the intestine and liver makes it difficult to determine the relative contribution of P-gp to a specific drug interaction. [Pg.241]

Jacob LP, Malhotra D, Chan L, Shapiro JI. Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil. Am J Kidney Dis 1999 33(2) 301-3. [Pg.609]

Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DW. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994 14(4) 471-81. [Pg.768]


See other pages where Diltiazem Cyclosporine is mentioned: [Pg.597]    [Pg.597]    [Pg.371]    [Pg.466]    [Pg.479]    [Pg.202]    [Pg.408]    [Pg.1816]    [Pg.99]    [Pg.122]    [Pg.134]    [Pg.284]    [Pg.33]    [Pg.82]    [Pg.99]    [Pg.134]    [Pg.134]    [Pg.284]    [Pg.1583]    [Pg.1595]    [Pg.489]    [Pg.491]    [Pg.346]    [Pg.124]   
See also in sourсe #XX -- [ Pg.1027 ]




SEARCH



Cyclosporin

Cyclosporin/cyclosporine

Cyclosporines

Cyclosporins

Cyclosporins Cyclosporin

Diltiazem

© 2024 chempedia.info